IL161812A0 - Apo2 ligand/trail formulations - Google Patents

Apo2 ligand/trail formulations

Info

Publication number
IL161812A0
IL161812A0 IL16181202A IL16181202A IL161812A0 IL 161812 A0 IL161812 A0 IL 161812A0 IL 16181202 A IL16181202 A IL 16181202A IL 16181202 A IL16181202 A IL 16181202A IL 161812 A0 IL161812 A0 IL 161812A0
Authority
IL
Israel
Prior art keywords
formulations
trail
apo2 ligand
trail formulations
methods
Prior art date
Application number
IL16181202A
Other languages
English (en)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL161812A0 publication Critical patent/IL161812A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
IL16181202A 2001-11-13 2002-11-12 Apo2 ligand/trail formulations IL161812A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33824901P 2001-11-13 2001-11-13
PCT/US2002/036251 WO2003042344A2 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations

Publications (1)

Publication Number Publication Date
IL161812A0 true IL161812A0 (en) 2005-11-20

Family

ID=23324037

Family Applications (3)

Application Number Title Priority Date Filing Date
IL16181202A IL161812A0 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations
IL161812A IL161812A (en) 2001-11-13 2004-05-06 STABLE FORMULATION OF Apo-2 LIGAND AND A METHOD FOR MANUFACTURING IT
IL197705A IL197705A0 (en) 2001-11-13 2009-03-19 STABLE FORMULATION OF Apo2 LIGNAD, A METHOD OF MAKING CRYSTALIZED Apo2 LIGNAD AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL161812A IL161812A (en) 2001-11-13 2004-05-06 STABLE FORMULATION OF Apo-2 LIGAND AND A METHOD FOR MANUFACTURING IT
IL197705A IL197705A0 (en) 2001-11-13 2009-03-19 STABLE FORMULATION OF Apo2 LIGNAD, A METHOD OF MAKING CRYSTALIZED Apo2 LIGNAD AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS

Country Status (11)

Country Link
US (3) US7741282B2 (xx)
EP (3) EP1450847B1 (xx)
JP (2) JP2005521640A (xx)
AT (1) ATE482716T1 (xx)
CA (1) CA2466054C (xx)
DE (1) DE60237841D1 (xx)
DK (1) DK1450847T3 (xx)
ES (1) ES2351786T3 (xx)
IL (3) IL161812A0 (xx)
PT (1) PT1450847E (xx)
WO (1) WO2003042344A2 (xx)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ537920A (en) * 1999-06-28 2006-10-27 Genentech Inc An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP1585771A4 (en) * 2002-12-31 2006-11-29 Altus Pharmaceuticals Inc COMPLEXES OF PROTEIN CRYSTALS AND IONIC POLYMERS
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CA2611200A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised il-21 compositions
EP1915626B1 (en) * 2005-08-16 2011-11-09 Genentech, Inc. Apoptosis sensitivity to apo2l/trail by testing for galnac-t14 expression in cells/tissues
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
CN101822820A (zh) 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CN101820907B (zh) 2007-08-15 2013-05-01 切尔卡西亚有限公司 针对过敏原去敏化的肽
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
EP2350271B1 (en) 2008-11-20 2016-01-27 Biogen MA Inc. Arginine inactivation of enveloped viruses
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
DE102008064553B4 (de) * 2008-12-22 2015-05-13 Technische Universität Dresden Verfahren zum Nachweis und/oder zur Identifizierung hormonell wirksamer Substanzen
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
CN102666568B (zh) 2009-12-18 2015-12-09 杰特有限公司 纯化多肽的方法
WO2011134979A2 (en) * 2010-04-27 2011-11-03 Scil Technology Gmbh Stable mia/cd-rap formulation
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
EP2704735A1 (en) 2011-05-03 2014-03-12 Genentech, Inc. Vascular disruption agents and uses thereof
CN104284676B (zh) * 2012-05-11 2018-11-27 诺华股份有限公司 用于纯化单克隆抗体的结晶方法
AU2014279627A1 (en) * 2013-06-09 2015-12-03 Efranat Ltd. Compositions comprising Gc- macrophage activating factor and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5829958B2 (ja) * 1977-03-07 1983-06-25 工業技術院長 タンパク質結晶の形成方法
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS60126084A (ja) * 1983-12-13 1985-07-05 Toyo Jozo Co Ltd グリセロリン酸オキシダーゼの安定化法
JPS62283932A (ja) 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤
EP0257956B2 (en) 1986-08-19 2000-11-22 Genentech, Inc. Use of polypeptide growth factors and cytokines for the manufacture of a device and of a dispersion
JP2602850B2 (ja) * 1987-10-27 1997-04-23 富士通株式会社 単結晶作製方法
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
ES2253753T3 (es) * 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CN1624128A (zh) 1997-03-17 2005-06-08 人类基因组科学公司 包含死亡结构域的受体－5
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
IL132304A0 (en) 1997-04-16 2001-03-19 Amgen Inc Osteoprotegerin binding proteins and receptors
WO1998046643A1 (en) 1997-04-16 1998-10-22 Millennium Biotherapeutics, Inc. TUMOR NECROSIS FACTOR RECEPTOR RELATED PROTEINS TANGO-63d AND TANGO-63e
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
CN1266354A (zh) 1997-07-02 2000-09-13 普罗克特和甘保尔公司 向食品中添加受控量成分的悬浮液
AU8400398A (en) 1997-07-11 1999-02-08 Trustees Of The University Of Pennsylvania, The Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
CA2301202A1 (en) 1997-08-15 1999-02-25 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
JP2001513994A (ja) 1997-08-26 2001-09-11 ジェネンテク・インコーポレイテッド Ｒｔｄレセプター
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO1999036535A1 (en) 1998-01-15 1999-07-22 Genentech, Inc. Apo-2 ligand
JP4194681B2 (ja) * 1998-01-20 2008-12-10 太陽化学株式会社 可溶性γ−リベチン複合体の製造法
CA2324494A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
GB2349636A (en) 1998-09-17 2000-11-08 Adv Liquid Packaging Corp Resealable can
FR2783596B1 (fr) 1998-09-23 2001-03-09 Eurokera Ensemble prefabrique destine a la realisation de tables de cuisson
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
NZ537920A (en) 1999-06-28 2006-10-27 Genentech Inc An isolated Apo-2 ligand variant polypeptide comprising an amino acid sequence which differs from the native sequence Apo-2 ligand
AUPQ312699A0 (en) 1999-09-28 1999-10-21 Electrical Moulded Components Pacific Pty Ltd Electrical reticulation apparatus
JP2003510288A (ja) 1999-09-30 2003-03-18 ザ トラスティーズ オヴ ザ ユニヴァーシティー オヴ ペンシルバニア Ｔｒａｉｌ：自己免疫性炎症及び細胞周期進行の阻害剤
HUP0203133A3 (en) 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
PT1129720E (pt) * 2000-02-29 2004-08-31 Pfizer Prod Inc Factor estimulador de colonias de granulocitos estabilizado
EP1303293B1 (en) 2000-07-27 2008-12-03 Genentech, Inc. Sequential administration of cpt-11 and apo-2l polypeptide
EP2348043A1 (en) * 2001-10-02 2011-07-27 Genentech, Inc. APO-2 ligand variants and uses thereof
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations

Also Published As

Publication number Publication date
DE60237841D1 (de) 2010-11-11
CA2466054A1 (en) 2003-05-22
US8470969B2 (en) 2013-06-25
IL197705A0 (en) 2009-12-24
EP2322165A1 (en) 2011-05-18
IL161812A (en) 2013-02-28
EP1450847A4 (en) 2007-08-29
DK1450847T3 (da) 2010-12-13
WO2003042344A2 (en) 2003-05-22
PT1450847E (pt) 2011-01-05
EP2332531B1 (en) 2019-07-10
ATE482716T1 (de) 2010-10-15
US20050020498A1 (en) 2005-01-27
JP2005521640A (ja) 2005-07-21
CA2466054C (en) 2012-01-03
US20110269947A1 (en) 2011-11-03
JP2009108040A (ja) 2009-05-21
EP1450847B1 (en) 2010-09-29
EP2332531A1 (en) 2011-06-15
US7741282B2 (en) 2010-06-22
WO2003042344A3 (en) 2003-11-27
EP1450847A2 (en) 2004-09-01
JP5042959B2 (ja) 2012-10-03
US20050080006A1 (en) 2005-04-14
ES2351786T3 (es) 2011-02-10

Similar Documents

Publication Publication Date Title
IL161812A0 (en) Apo2 ligand/trail formulations
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
AU4673099A (en) Use of bioadhesives and adjuvants for the mucosal delivery of antigens
WO2003016282A3 (en) Substituted 1h-dihydropyrazoles, their preparation and use
EP1649006A4 (en) EXO-SPECIFIC AMYLASE POLYPEPTIDES, THESE POLYPEPTIDE-CODING NUCLEIC ACIDS, AND USES THEREOF
HK1149930A1 (en) Pyrimidineamines as angiogenesis modulators
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
IL172512A0 (en) Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
IL185142A0 (en) Lentiviral packaging constructs
WO2000018914A3 (en) Novel dkr polypeptides
WO2007051164A3 (en) Toll like receptor 3 modulators, methods and uses
PL344475A1 (en) Bridged indenopyrrolocarbazoles
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
WO2004001009A3 (en) Apo-2 ligand/trail variants and uses thereof
HK1066213A1 (en) Tricyclic imidazopyridines.
PL1680430T3 (pl) Sposoby wytwarzania postaci i (s)-(+)-wodorosiarczanu klopidogrelu
WO2003092632A3 (en) Cyclic peptide anti-cancer agents and methods
EP0897011A3 (en) Novel arginine deiminase
PL366629A1 (en) 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
EP1613606A4 (en) PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES
SG158098A1 (en) Toll like receptor 3 antagonists, methods and uses
WO2003027242A3 (en) Fas ligand
EP0835936A3 (en) Arginyl tRNA synthase
WO2004072241A3 (en) Compositions and methods for cleaving iap
AU2001250322A1 (en) Novel, central nervous protein, that modulates k+ flows